Why Biotech Stock ArQule Soared 108% in December

Why Biotech Stock ArQule Soared 108% in December

Source: 
Motley Fool
News Tags: 
snippet: 

We can attribute ArQule stock's powerful performance last month to Merck's (NYSE:MRK) Dec. 9 announcement that it plans to acquire ArQule. Shares surged to a closing gain of 104% that day.